Opiant Pharmaceuticals Stock Up 0.1 %
Shares of OPNT opened at $20.09 on Tuesday. The firm has a 50 day simple moving average of $11.56 and a two-hundred day simple moving average of $11.92. The company has a market cap of $103.74 million, a P/E ratio of -3.06 and a beta of 0.51. Opiant Pharmaceuticals has a one year low of $7.34 and a one year high of $37.71. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.48 and a quick ratio of 5.48.
Institutional Trading of Opiant Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the business. HealthInvest Partners AB acquired a new position in Opiant Pharmaceuticals during the first quarter worth about $386,000. Essex Investment Management Co. LLC grew its holdings in shares of Opiant Pharmaceuticals by 2.5% during the 1st quarter. Essex Investment Management Co. LLC now owns 32,040 shares of the technology company’s stock valued at $686,000 after purchasing an additional 777 shares during the last quarter. JPMorgan Chase & Co. increased its position in Opiant Pharmaceuticals by 10.7% during the 1st quarter. JPMorgan Chase & Co. now owns 7,466 shares of the technology company’s stock worth $160,000 after purchasing an additional 723 shares in the last quarter. Ovata Capital Management Ltd acquired a new position in Opiant Pharmaceuticals during the 1st quarter worth approximately $2,525,000. Finally, Acadian Asset Management LLC lifted its stake in Opiant Pharmaceuticals by 62.0% in the 1st quarter. Acadian Asset Management LLC now owns 116,478 shares of the technology company’s stock valued at $2,494,000 after purchasing an additional 44,562 shares during the last quarter. 36.12% of the stock is currently owned by institutional investors.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
- Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.